secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001437749-26-005537
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals receives FDA approval for DESMODA oral solution for central diabetes insipidus
--------------------------------------------------------------------------------

- FDA approved DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus in all ages; first approved oral liquid formulation.
- Commercial launch expected March 9; product available exclusively through Anovo specialty pharmacy.
- Eton estimates >13,000 U.S. patients; potential peak sales of $30-$50M annually.
- Patent protection through 2044; product leverages existing pediatric endocrinology rare disease sales team.
- Key safety warning: risk of hyponatremia; fluid restriction recommended; contraindicated in moderate to severe renal impairment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/0001437749-26-005537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/eton20260223_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-005537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer